Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides, page-5

Gist of webcast to me:

Pathological data need to be analysed and multivariate analysis performed and see specially what was the key to better results in subgroups. That can lead to two things (perhaps amongst others); (1) We know what group of patients it work in and that may lead to further knowledge about how the cell responses and then how efti can be used beyond oncology for example (2) we will know what to perhaps change/do to help with results in the subgroup that dragged the average down.

So, as i have said before, H2, or end 2020 is the time we can call this (APEC).

... and then there are other trials we are conducting ... please listen to webcast before you post about prospects of CR too.